|Day Low/High||3.13 / 3.38|
|52 Wk Low/High||0.80 / 4.21|
Eight favorite stock ideas in the small-cap biotech space.
Here's the difference between the two, using two biotech companies, Mannkind and Editas.
These rules can help investors who are digging through the rubble that 2018 left behind in the biotech sector.
Mannkind stock is suffering, and the company appears to be in trouble.
The stock has taken a beating, but users of Afrezza are loyal to the drug.
2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!
In 'What's Ahead on Wall Street' for the week of March 14, we have a mix of both earnings and economic data.
Shareholders should have been running from the drugmaker long before Tuesday's news that partner Sanofi was leaving first.
Meet the new (and likely temporary, 90-year-old) boss, same as the old boss.
Can a 'fair value' really be determined for the unprofitable Tesla, SunEdison, Plug Power and Mannkind?
Selection of stocks is tailor made for investor, given market parameters.
TheStreet's Jim Cramer is asked for advice on Mannkind, which has doubled in value after an FDA panel recommended approval of its insulin drug Afreeza.
Disney's 'Frozen' skated its way into history this week, becoming the highest-grossing animated movie ever with a total worldwide gross of $1.07 billion and counting.
TheStreet's Jim Cramer says he is completely neutral on Mannkind and sometimes it's better to admit you don't know where something is going.
ADP private payrolls data missed expectations for March, but the revision upward of February's number seemed to slightly satisfy traders.